Nanjing Pharmaceutical Co (SHSE:600713) Total Liabilities : ¥25,107 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Nanjing Pharmaceutical Co Total Liabilities?

Nanjing Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥25,107 Mil.

Nanjing Pharmaceutical Co's quarterly Total Liabilities declined from Sep. 2023 (¥26,136.32 Mil) to Dec. 2023 (¥21,155.31 Mil) but then increased from Dec. 2023 (¥21,155.31 Mil) to Mar. 2024 (¥25,107.08 Mil).

Nanjing Pharmaceutical Co's annual Total Liabilities increased from Dec. 2021 (¥20,651.95 Mil) to Dec. 2022 (¥24,956.07 Mil) but then declined from Dec. 2022 (¥24,956.07 Mil) to Dec. 2023 (¥21,155.31 Mil).

Nanjing Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Nanjing Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing Pharmaceutical Co Total Liabilities Chart

Nanjing Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

17,445.57

18,815.09

20,651.95

24,956.07

21,155.31

Nanjing Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															25,954.08	26,429.97	26,136.32	21,155.31	25,107.08

Nanjing Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nanjing Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	18566.034	+	(2236.799	+	352.472
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	21,155

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	28410.232	-	7254.926
	=	21,155

Nanjing Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	21159.971	+	(3599.515	+	347.594
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	25,107

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	32563.723	-	7456.643
	=	25,107

Nanjing Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Nanjing Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing Pharmaceutical Co (SHSE:600713) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing Pharmaceutical Co Ltd (SHSE:600713) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 486 Zhongshan East Road, Nanjing, Jiangsu, CHN, 210002

Website

http://www.guangyuyuan.com

Nanjing Pharmaceutical Co Ltd is engaged in the pharmaceutical service business.

Executives

Xiao Hong	senior management
Peng Yu Ping	senior management
She Ping	Supervisors
Jiang Xiao Jun	senior management
Teng Xue Wu	senior management
Zhou Jian Jun	senior management
Li Yi	Director
Huang Yan Li	Supervisors
Tang Jian Zhong	senior management
Zhang Yan Hui	senior management
Zhou Yao Ping	Director
Wang Hui Qing	senior management
He Jin Geng	senior management
Ding Feng Jun	Director
Liang Yu Tang	Director

Nanjing Pharmaceutical Co (SHSE:600713) Headlines

No Headlines